NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
מצבים רפואיים
Neuroblastoma
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Children's Hospital Los Angeles, Los Angeles, California, United States
Contact: Study coordinator (Araz Marachelian, MD)UCSF Benioff Children's Hospital, San Francisco, California, United States
Contact: Study coordinator (Kieuhoa Vo, MD)Children's Hospital Colorado, Aurora, Colorado, United States
Contact: Study coordinator (Margaret Macy, MD)Comer Children's Hospital, University of Chicago, Chicago, Illinois, United States
Boston Children's Hospital, Dana-Farber Cancer Institute., Boston, Massachusetts, United States
Contact: Study coordinator (Suzanne Shusterman, MD)C.S Mott Children's Hospital, Ann Arbor, Michigan, United States
Contact: Study coordinator (Rajen Mody, MD)Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Contact: Study coordinator (Katherine Sommers, MD)Nationwide Children's Hospital, Columbus, Ohio, United States
Contact: Study coordinator (Keri Streby, MD)Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Yael Mosse, MD)St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Contact: Study coordinator (Sara Federico, MD)University of Texas Southwestern, Dallas, Texas, United States
Contact: Study coordinator (Tanya Watt, MD)Cook Children's Medical Center, Fort Worth, Texas, United States
Contact: Study coordinator (Chelsee Greer, DO)Seattle Children's Hospital, Seattle, Washington, United States
Contact: Study coordinator (Mark Fluchel, MD)
מובילי המחקר
Keri Streby, MD
Study Chair
Nationwide Children's Hospital
Mark Ranalli, MD
Study Chair
Nationwide Children's Hospital